drugset / Trial / NCT06443762
First Human Trial of Targeting MDM2/MDMX PET Imaging
NaSingle-groupOpen-labelDiagnostic
Summary
Investigation of the Radiotracer Uptake of \[68Ga\] MDM2/MDMX Peptide at Lesion Sites in Patients with Malignant Tumors, and Evaluation of the Capability of \[68Ga\] MDM2/MDMX Peptide to Detect Overexpression of MDM2/MDMX in Tumor Patients, Particularly Those with Recurrent or Advanced Disease.
Timeline
- Start
- 2025-01-03
- Primary completion
- 2025-05-01
- Completion
- 2025-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [68Ga] MDM2/MDMX Peptide | Peptide | 0.05 unknown | Intravenous |
| Subject | [68Ga] MDM2/MDMX Peptide | Peptide | 0.1 unknown | Intravenous |
Indications
No indication recorded.